Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-06-09 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated June 9, 2022, announcing a positive opinion from European authorities regarding the marketing authorization for Dysport® for treating urinary incontinence. It details clinical trial results (Phase III CONTENT program) and provides company background. This type of announcement, which communicates a significant regulatory milestone or key business development outside of routine financial reporting (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and content focus on a specific regulatory event and clinical data summary, it functions as a broad corporate announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ) nor a specific management/governance document (MANG, CGR, DEF 14A), and it is not merely announcing the publication of another report (RPA), the most appropriate general category for a significant, non-standard regulatory/business update is RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory announcements. The length (11,982 chars) confirms it is substantial content, not just a brief notice.
2022-06-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated June 9, 2022, announcing a positive opinion received in Europe for their drug Dysport® regarding a specific medical condition (urinary incontinence). It details clinical trial results (CONTENT program), provides background on the condition and the drug, and includes standard investor relations disclaimers and contact information. This format—a formal announcement of a significant business/clinical development intended for media and investors—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change announcement, and it focuses on a key business development (regulatory milestone), it aligns best with the 'Earnings Release' category, which often includes major operational/clinical updates alongside or instead of pure financial figures, or the general 'Regulatory Filings' (RNS) if it were less structured. Given the structure and content (announcement of a positive opinion based on clinical data), it functions as a major corporate update, often released around earnings periods or as a standalone news item. However, since it is not explicitly an 'Earnings Release' detailing quarterly/periodical financial results (Code: ER), and it is a specific, non-standard announcement, the most appropriate general category for significant, non-standard corporate news that doesn't fit the other specific codes is 'Regulatory Filings' (RNS). It is a formal announcement intended for public disclosure.
2022-06-09 English
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 1% confidence The document explicitly details a 'Disclosure transaction in own shares' occurring between specific dates (01/06/2022 and 03/06/2022). It presents aggregated data on the volume and price of shares acquired by the issuer (IPSEN). This content directly matches the definition for 'Transaction in Own Shares' (share repurchase/issuance), which corresponds to the filing code POS.
2022-06-07 English
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 01 au 03 Juin 2022" (Declaration of transactions on own shares carried out from June 1 to 3, 2022). The content is a table detailing the volume, weighted average price, and date of transactions involving the company's own shares. This directly corresponds to the definition of a 'Transaction in Own Shares' report, which is classified as 'POS'. The document is a direct report of the transactions, not an announcement of a report's publication.
2022-06-07 French
Acquisition ou cession des actions de l'émetteur / Descriptif du programme de rachat
Transaction in Own Shares Classification · 1% confidence The document explicitly announces that Ipsen has mandated an investment services provider to repurchase 125,000 shares to cover its employee free share award program. This action—the company buying back its own shares—directly corresponds to the definition of 'Transaction in Own Shares'. The code for this is POS. The document is a formal announcement detailing the transaction, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the core substance of the transaction itself.
2022-06-01 French
Acquisition or disposal of the issuer's own shares / Description of the buyback program
Transaction in Own Shares Classification · 1% confidence The document explicitly announces that Ipsen has initiated a share buy-back program to cover its employee free share-allocation plan. It details the number of shares (125,000) and the purpose. This action falls directly under the category of a company repurchasing or issuing its own shares for specific corporate purposes, which corresponds to the 'Transaction in Own Shares' definition. The code for this is POS.
2022-06-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.